×
About 5,283 results

ALLMedicine™ Hypercalcemia Center

Research & Reviews  1,404 results

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04634552

Dec 3rd, 2021 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...

Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circul...
https://doi.org/10.1001/jama.2021.20929
JAMA Vallentin MF, Granfeldt A et. al.

Dec 1st, 2021 - It is unclear whether administration of calcium has a beneficial effect in patients with cardiac arrest. To determine whether administration of calcium during out-of-hospital cardiac arrest improves return of spontaneous circulation in adults. Thi...

Severe hypercalcemia requiring acute hemodialysis: A retrospective cohort study with in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585552
The American Journal of Emergency Medicine; Bentata Y, Benabdelhak M et. al.

Nov 26th, 2021 - The Covid-19 pandemic has had dramatic consequences on the progression of numerous pathologies, especially neoplastic ones. The orientation of hospital activities toward the care of patients with SARS-Cov2 infection has caused significant delays i...

Case Report: Gastric plasmacytoma resistant to radiation therapy.
https://doi.org/10.1080/00325481.2021.2008726
Postgraduate Medicine; Weidenbaum C

Nov 24th, 2021 - Plasma cell neoplasms are a group of diseases involving the malignant proliferation of plasma cells. One common type of plasma cell neoplasm is multiple myeloma, which typically occurs diffusely in the bone marrow. It can manifest with a variety o...

Reversible Cerebral Vasoconstriction Syndrome in a Background of Eclampsia Responding t...
https://doi.org/10.12659/AJCR.934528
The American Journal of Case Reports; Hadhiah KM, Alshagawi ZA et. al.

Nov 17th, 2021 - BACKGROUND Reversible cerebral vasoconstriction syndrome (RCVS) is a rare neurological disorder with a complex physiopathology that is not fully understood. Suggested underlying mechanisms include failure of autoregulation, endothelial dysfunction...

see more →

Guidelines  3 results

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494249
Journal of Clinical Oncology : Official Journal of the Am... Cook LB, Fuji S et. al.

Jan 19th, 2019 - Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diver...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 12th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

SEOM guidelines on hydroelectrolytic disorders.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239780
Clinical & Translational Oncology : Official Publication ... De las Peñas R, Escobar Y et. al.

Oct 12th, 2014 - Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneopl...

see more →

Drugs  454 results see all →

Clinicaltrials.gov  53 results

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04634552

Dec 3rd, 2021 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...

Circulating miRNA in Primary Hyperparathyroidism
https://clinicaltrials.gov/ct2/show/NCT03931109

Nov 16th, 2021 - Osteoporosis and osteopenia are chronic diseases disproportionately affecting the elderly. In the United States, the prevalence of osteoporosis is projected to increase from 10 million in 2005 to 14 million in 2025, due to population aging. Simila...

Studies of Inherited Diseases of Metabolism
https://clinicaltrials.gov/ct2/show/NCT00001345

Oct 18th, 2021 - Familial multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric (or familial benign) hypercalcemia (FHH), hyperparathyroidism - jaw tumor syndrome (HPT-JT), other causes of familial isolated hyperparathyroidism (FIHP), and pseudohypopa...

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
https://clinicaltrials.gov/ct2/show/NCT04177823

Oct 13th, 2021 - Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure. belantamab mafodotin was well tolerated in previous studies with at least one dose of belantamab ...

Evaluation of the Effects of Calcitriol's in the Neurological Symptoms of Friedreich's Ataxia Patients
https://clinicaltrials.gov/ct2/show/NCT04801303

Sep 21st, 2021 - Friedreich's Ataxia (FA) is a recessive hereditary disease due to GAA (Guanine-Adenosine-Adenosine) triplet repeats in the FXN (Frataxin) gene. This gene codifies for the frataxin protein, the lack of which produces the neurological and cardiac sy...

see more →

News  195 results

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer
https://www.onclive.com/view/enobosarm-shows-clinical-benefit-in-ar-er-metastatic-breast-cancer

Oct 6th, 2021 - Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented durin...

Update on Bone Disease in Multiple Myeloma
https://www.onclive.com/view/update-on-bone-disease-in-multiple-myeloma

Aug 17th, 2021 - Asher Chanan-Khan, MD Bone disease in patients with multiple myeloma should not be taken lightly, stated Asher Chanan-Khan, MD, the new chair of the Division of Hematology/Oncology at the Mayo Clinic in Jacksonville, Florida. Chanan-Khan updated...

Talking Tumors: Filling Data Gaps in Multiple Myeloma
https://www.onclive.com/view/talking-tumors-filling-data-gaps-in-multiple-myeloma

Aug 17th, 2021 - We recently traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma. Although the treatment paradigm in multiple myeloma is guided by transplant eligibility, and grounded in the use of immunomodulatory drugs, pr...

NCCN Guidelines Include an Abundance of Options Across Multiple Myeloma Paradigm
https://www.onclive.com/view/nccn-guidelines-include-an-abundance-of-options-across-multiple-myeloma-paradigm

Aug 17th, 2021 - The National Comprehensive Cancer Network (NCCN) guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommen...

Hypercalcemia? When to Worry
https://www.medscape.com/viewarticle/955925

Aug 10th, 2021 - This transcript has been edited for clarity. Matthew F. Watto, MD: We are back. Paul, what are we talking about today? Paul N. Williams: MD: We're going to be discussing our podcast on hypercalcemia with the wildly enthusiastic and incredibly smar...

see more →

Patient Education  4 results see all →